[symbol: see text] Tiagabine: add-on treatment for partial seizures.
Up to 30% of patients with epilepsy have seizures resistant to available treatments. We consider here the place of [symbol: see text] tiagabine (Gabitril-Sanofi-Synthelabo), which was recently introduced as an "add-on therapy for partial seizures with or without secondary generalisation where control is not achieved by optimal doses of at least one other anti-epileptic".
D000927:Anticonvulsants / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D006801:Humans; D014179:Neurotransmitter Uptake Inhibitors / Q000627:therapeutic use*; D009557:Nipecotic Acids / Q000627:therapeutic use*; D000078308:Tiagabine
D000927:Anticonvulsants; D014179:Neurotransmitter Uptake Inhibitors; D009557:Nipecotic Acids; D000078308:Tiagabine